These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

680 related items for PubMed ID: 24757085

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Radiotherapy for solitary plasmacytoma of bone and soft tissue: outcomes and prognostic factors.
    Suh YG, Suh CO, Kim JS, Kim SJ, Pyun HO, Cho J.
    Ann Hematol; 2012 Nov; 91(11):1785-93. PubMed ID: 22752147
    [Abstract] [Full Text] [Related]

  • 3. [Clinical analysis of multiple myeloma with extramedullary plasmacytomas].
    Li X, Sun WJ, Chen SL, Zhong YP, An N, Hu Y, Zhang JJ, Liu XH.
    Zhonghua Yi Xue Za Zhi; 2012 Mar 27; 92(12):838-41. PubMed ID: 22781459
    [Abstract] [Full Text] [Related]

  • 4. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
    Ahn JS, Jung SH, Yang DH, Bae SY, Kim YK, Kim HJ, Lee JJ.
    Clin Lymphoma Myeloma Leuk; 2014 Oct 27; 14(5):389-94. PubMed ID: 24630919
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, Desai A, Cakana A, Liu K, van de Velde H, Esseltine DL, Moreau P.
    J Clin Oncol; 2013 Sep 10; 31(26):3279-87. PubMed ID: 23897961
    [Abstract] [Full Text] [Related]

  • 9. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF.
    Haematologica; 2008 Apr 10; 93(4):560-5. PubMed ID: 18322252
    [Abstract] [Full Text] [Related]

  • 10. Clinical and prognostic features of plasmacytomas: a multicenter study of Turkish Oncology Group-Sarcoma Working Party.
    Kilciksiz S, Celik OK, Pak Y, Demiral AN, Pehlivan M, Orhan O, Tokatli F, Agaoglu F, Zincircioglu B, Atasoy BM, Ozseker N, Yersal O, Niang U, Haydaroglu A, Turkish Oncology Group-Sarcoma Working Party.
    Am J Hematol; 2008 Sep 10; 83(9):702-7. PubMed ID: 18543343
    [Abstract] [Full Text] [Related]

  • 11. Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas.
    Fukushima T, Nakamura T, Miki M, Sakai T, Iwao H, Nakajima A, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Hirose Y, Umehara H.
    Anticancer Res; 2010 Sep 10; 30(9):3791-4. PubMed ID: 20944171
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years.
    Barzenje DA, Kolstad A, Ghanima W, Holte H.
    Hematol Oncol; 2018 Feb 10; 36(1):217-223. PubMed ID: 28393375
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Solitary plasmacytomas of bone and extramedullary plasmacytomas].
    Yang D, Fan S, Tao H.
    Zhonghua Zhong Liu Za Zhi; 1996 Jan 10; 18(1):41-4. PubMed ID: 8732111
    [Abstract] [Full Text] [Related]

  • 17. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S.
    Cancer; 2010 Jul 01; 116(13):3143-51. PubMed ID: 20564642
    [Abstract] [Full Text] [Related]

  • 18. [Bortezomib-based chemotherapy for patients with multiple myeloma: a single center experience].
    Liang Z, Ren H, Cen X, Li Y, Wang L, Ou J, Dong Y, Yin Y, Wang W, Liu W, Wang Q, Qiu Z, Wang M, Xu W, Sun Y.
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar 01; 35(3):225-30. PubMed ID: 24666489
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical analysis of 40 multiple myeloma patients with extramedullary plasmacytoma of the head.
    Sun WJ, Zhang JJ, An N, Shen M, Huang ZX, Li X.
    J Int Med Res; 2016 Dec 01; 44(6):1462-1473. PubMed ID: 28322099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.